{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Cancer&page=39", "query": { "condition": "Breast Cancer", "page": 39 }, "page_size": 10 }, "pagination": { "page": 39, "page_size": 10, "total_count": 7078, "total_pages": 708, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Cancer&page=40&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Cancer&page=38&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-31T12:56:18.869Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05645536", "title": "Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "TOL2506", "type": "DRUG" }, { "name": "Tamoxifen", "type": "DRUG" }, { "name": "Letrozole tablets", "type": "DRUG" }, { "name": "Anastrozole Tablets", "type": "DRUG" }, { "name": "Exemestane Tablets", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tolmar Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "51 Years", "sex": "ALL", "summary": "18 Years to 51 Years" }, "enrollment_count": 250, "start_date": "2022-12-28", "completion_date": "2030-03", "has_results": false, "last_update_posted_date": "2026-10-23", "last_synced_at": "2026-10-31T12:56:18.869Z", "location_count": 17, "location_summary": "Greenbrae, California • Fort Lauderdale, Florida • Lexington, Kentucky + 14 more", "locations": [ { "city": "Greenbrae", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Columbia", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05645536" }, { "nct_id": "NCT00593827", "title": "Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Ixabepilone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "R-Pharm", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 176, "start_date": "2008-05", "completion_date": "2010-08", "has_results": true, "last_update_posted_date": "2016-03-10", "last_synced_at": "2026-10-31T12:56:18.869Z", "location_count": 57, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Sedona, Arizona + 49 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sedona", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Murrieta", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00593827" }, { "nct_id": "NCT05080842", "title": "A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "AC682", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Accutar Biotechnology Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2021-11-12", "completion_date": "2024-04-04", "has_results": false, "last_update_posted_date": "2025-02-13", "last_synced_at": "2026-10-31T12:56:18.869Z", "location_count": 5, "location_summary": "Denver, Colorado • Orlando, Florida • Sarasota, Florida + 2 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05080842" }, { "nct_id": "NCT00074269", "title": "Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "graft-versus-tumor induction therapy", "type": "BIOLOGICAL" }, { "name": "therapeutic allogeneic lymphocytes", "type": "BIOLOGICAL" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "FEMALE", "summary": "18 Years to 60 Years · Female only" }, "enrollment_count": 5, "start_date": "2003-07", "completion_date": "2008-03", "has_results": true, "last_update_posted_date": "2023-06-05", "last_synced_at": "2026-10-31T12:56:18.869Z", "location_count": 1, "location_summary": "La Jolla, California", "locations": [ { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00074269" }, { "nct_id": "NCT01480583", "title": "GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Brain Metastases" ], "interventions": [ { "name": "GRN1005", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "18F-FLT", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Angiochem Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 85, "start_date": "2011-10", "completion_date": "2015-10", "has_results": false, "last_update_posted_date": "2016-07-13", "last_synced_at": "2026-10-31T12:56:18.869Z", "location_count": 2, "location_summary": "Harvey, Illinois • Rockville, Maryland", "locations": [ { "city": "Harvey", "state": "Illinois" }, { "city": "Rockville", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01480583" }, { "nct_id": "NCT02764541", "title": "Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Letrozole", "type": "DRUG" }, { "name": "Tamoxifen", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Endocrine Therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 195, "start_date": "2016-05-24", "completion_date": "2031-04", "has_results": true, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-10-31T12:56:18.869Z", "location_count": 11, "location_summary": "Stamford, Connecticut • Brewer, Maine • Boston, Massachusetts + 5 more", "locations": [ { "city": "Stamford", "state": "Connecticut" }, { "city": "Brewer", "state": "Maine" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02764541" }, { "nct_id": "NCT07261631", "title": "Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Ductal Adenocarcinoma", "Non-Small Cell Lung Cancer", "HR+/HER2- Ductal and Lobular Breast Cancer", "Triple Negative Breast Cancer", "Colorectal Cancer", "Soft Tissue Sarcoma" ], "interventions": [ { "name": "68Ga-NNS309", "type": "DRUG" }, { "name": "177Lu-DFC413", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 180, "start_date": "2025-11-24", "completion_date": "2029-05-09", "has_results": false, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-10-31T12:56:18.869Z", "location_count": 1, "location_summary": "Princeton, New Jersey", "locations": [ { "city": "Princeton", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT07261631" }, { "nct_id": "NCT01761877", "title": "NSAID Effects on Clinical and Imaging Breast Biomarkers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Inflammation", "Cancer", "Pain", "Hypertension" ], "interventions": [ { "name": "Sulindac", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stony Brook University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "75 Years", "sex": "FEMALE", "summary": "Up to 75 Years · Female only" }, "enrollment_count": 114, "start_date": "2012-12", "completion_date": "2019-03-11", "has_results": true, "last_update_posted_date": "2023-02-10", "last_synced_at": "2026-10-31T12:56:18.869Z", "location_count": 2, "location_summary": "Tucson, Arizona • Stony Brook, New York", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Stony Brook", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01761877" }, { "nct_id": "NCT04205786", "title": "Vitamin B12 for Aromatase Inhibitors Associated Musculoskeletal Symptoms in Breast Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HR-positive Breast Cancer" ], "interventions": [ { "name": "Vitamin B12", "type": "DIETARY_SUPPLEMENT" }, { "name": "Blood collection", "type": "OTHER" }, { "name": "Brief Pain Inventory - Short Form survey", "type": "OTHER" }, { "name": "FACT-ES Trial Outcome Index (Version 4)", "type": "OTHER" }, { "name": "Questionnaire to Assess Adherence to Aromatase Inhibitors", "type": "OTHER" }, { "name": "Demographics Questionnaire", "type": "OTHER" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "OTHER" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 0, "start_date": "2021-08-12", "completion_date": "2025-12-01", "has_results": false, "last_update_posted_date": "2024-08-21", "last_synced_at": "2026-10-31T12:56:18.869Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04205786" }, { "nct_id": "NCT01138553", "title": "Preoperative Testing of the Anti-Progesterone Mifepristone in Early Stage Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Invasive Breast Cancer", "Ductal Carcinoma in Situ" ], "interventions": [ { "name": "Mifepristone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 4, "start_date": "2010-06", "completion_date": "2015-10", "has_results": false, "last_update_posted_date": "2019-07-08", "last_synced_at": "2026-10-31T12:56:18.869Z", "location_count": 1, "location_summary": "La Jolla, California", "locations": [ { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01138553" } ] }